188 related articles for article (PubMed ID: 37719859)
21. Classification of triple-negative breast cancers based on Immunogenomic profiling.
He Y; Jiang Z; Chen C; Wang X
J Exp Clin Cancer Res; 2018 Dec; 37(1):327. PubMed ID: 30594216
[TBL] [Abstract][Full Text] [Related]
22. Identification of molecular subtypes and a six-gene risk model related to cuproptosis for triple negative breast cancer.
Zhu B; Wang S; Wang R; Wang X
Front Genet; 2022; 13():1022236. PubMed ID: 36386788
[No Abstract] [Full Text] [Related]
23. Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
Suntiparpluacha M; Chanthercrob J; Sa-Nguanraksa D; Sitthikornpaiboon J; Chaiboonchoe A; Kueanjinda P; Jinawath N; Sampattavanich S
PeerJ; 2023; 11():e15350. PubMed ID: 37334114
[TBL] [Abstract][Full Text] [Related]
24. Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.
Su D; Chi M; Wang S; Di S; Zhang H; Lu Q; Yu Y; Xiong Y; Wei H; Lv Y; Zuo Y; Yang L
Brief Funct Genomics; 2022 May; 21(3):188-201. PubMed ID: 35348574
[TBL] [Abstract][Full Text] [Related]
25. Molecular analyses of triple-negative breast cancer in the young and elderly.
Aine M; Boyaci C; Hartman J; Häkkinen J; Mitra S; Campos AB; Nimeus E; Ehinger A; Vallon-Christersson J; Borg Å; Staaf J
Breast Cancer Res; 2021 Feb; 23(1):20. PubMed ID: 33568222
[TBL] [Abstract][Full Text] [Related]
26. Identification and validation of the cellular senescence-related molecular subtypes of triple negative breast cancer via integrating bulk and single-cell RNA sequencing data.
Ju G; Zeng K; Lu L; Diao H; Wang H; Li X; Zhou T
Am J Cancer Res; 2023; 13(2):569-588. PubMed ID: 36895975
[TBL] [Abstract][Full Text] [Related]
27. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
[TBL] [Abstract][Full Text] [Related]
28. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
29. Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers.
Lv Y; Lv D; Lv X; Xing P; Zhang J; Zhang Y
Front Genet; 2021; 12():616469. PubMed ID: 33815462
[TBL] [Abstract][Full Text] [Related]
30. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
Cancer Metab; 2017; 5():6. PubMed ID: 28852500
[TBL] [Abstract][Full Text] [Related]
31. Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer.
Su P; Peng Z; Xu B; Yang B; Jin F
PeerJ; 2021; 9():e12383. PubMed ID: 34900411
[TBL] [Abstract][Full Text] [Related]
32. Deep learning framework for comprehensive molecular and prognostic stratifications of triple-negative breast cancer.
Zhao S; Yan CY; Lv H; Yang JC; You C; Li ZA; Ma D; Xiao Y; Hu J; Yang WT; Jiang YZ; Xu J; Shao ZM
Fundam Res; 2024 May; 4(3):678-689. PubMed ID: 38933195
[TBL] [Abstract][Full Text] [Related]
33. Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer.
Wu J; Mamidi TKK; Zhang L; Hicks C
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545594
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Pyroptosis-Related Subtypes
Li C; Pan J; Jiang Y; Wu Y; Jin Z; Chen X
Front Genet; 2022; 13():788670. PubMed ID: 35386285
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Miyashita M; Bell JSK; Wenric S; Karaesmen E; Rhead B; Kase M; Kaneva K; De La Vega FM; Zheng Y; Yoshimatsu TF; Khramtsova G; Liu F; Zhao F; Howard FM; Nanda R; Beaubier N; White KP; Huo D; Olopade OI
Breast Cancer Res; 2023 May; 25(1):58. PubMed ID: 37231433
[TBL] [Abstract][Full Text] [Related]
36. Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer.
Ding R; Wang Y; Fan J; Tian Z; Wang S; Qin X; Su W; Wang Y
Front Oncol; 2023; 13():1108472. PubMed ID: 37377907
[TBL] [Abstract][Full Text] [Related]
37. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
38. High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer.
Liu X; Wu Y; Zhang Y; Bu D; Wu C; Lu S; Huang Z; Song Y; Zhao Y; Guo F; Ye P; Fu C; Shen L; Zhang J; Wang H; Duan X; Wu J
Front Oncol; 2021; 11():747300. PubMed ID: 34604090
[TBL] [Abstract][Full Text] [Related]
39. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
40. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Ahn SG; Kim SK; Shepherd JH; Cha YJ; Bae SJ; Kim C; Jeong J; Perou CM
Breast Cancer Res Treat; 2021 Jul; 188(1):165-178. PubMed ID: 33770313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
